Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis

Claudia Fabiani, Jurgen Sota, Antonio Vitale, Giacomo Emmi, Lorenzo Vannozzi, Daniela Bacherini, Giuseppe Lopalco, Silvana Guerriero, Vincenzo Venerito, Ida Orlando, Rossella Franceschini, Fiorella Fusco, Bruno Frediani, Mauro Galeazzi, Florenzo Iannone, Gian Marco Tosi, Luca Cantarini

Research output: Contribution to journalArticle

Abstract

© 2017, Taylor & Francis. All rights reserved. Purpose: To evaluate the 10-year drug retention rate of infliximab (IFX) in Behçet’s disease (BD)-related uveitis, the effect of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on drug survival and differences according to the lines of biologic treatment. Methods: Cumulative survival rates were studied using the Kaplan-Meier plot, while the Log-rank (Mantel-Cox) test was used to compare survival curves. Results: Forty patients (70 eyes) were eligible for analysis. The drug retention rates at 12-, 24-, 60- and 120-month follow-up were 89.03%, 86.16%, 75.66% and 47.11% respectively. No differences were identified according to the use of concomitant DMARDs (p = 0.20), while a statistically significant difference was observed in relation to the different lines of IFX treatment (p = 0.014). Visual acuity improved from baseline to the last follow-up visit (p = 0.047) and a corticosteroid-sparing effect was observed (p  < 0.0001). Conclusions: IFX retention rate in BD-uveitis is excellent and is not affected by concomitant DMARDs.
Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalOcular Immunology and Inflammation
DOIs
Publication statusAccepted/In press - Nov 4 2017

Fingerprint

Uveitis
Antirheumatic Agents
Pharmaceutical Preparations
Survival
Visual Acuity
Adrenal Cortex Hormones
Survival Rate
Infliximab
Therapeutics

Keywords

  • Behçet’s disease
  • drug retention rate
  • infliximab
  • treatment
  • uveitis

Cite this

Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis. / Fabiani, Claudia; Sota, Jurgen; Vitale, Antonio; Emmi, Giacomo; Vannozzi, Lorenzo; Bacherini, Daniela; Lopalco, Giuseppe; Guerriero, Silvana; Venerito, Vincenzo; Orlando, Ida; Franceschini, Rossella; Fusco, Fiorella; Frediani, Bruno; Galeazzi, Mauro; Iannone, Florenzo; Tosi, Gian Marco; Cantarini, Luca.

In: Ocular Immunology and Inflammation, 04.11.2017, p. 1-6.

Research output: Contribution to journalArticle

Fabiani, C, Sota, J, Vitale, A, Emmi, G, Vannozzi, L, Bacherini, D, Lopalco, G, Guerriero, S, Venerito, V, Orlando, I, Franceschini, R, Fusco, F, Frediani, B, Galeazzi, M, Iannone, F, Tosi, GM & Cantarini, L 2017, 'Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis', Ocular Immunology and Inflammation, pp. 1-6. https://doi.org/10.1080/09273948.2017.1391297
Fabiani, Claudia ; Sota, Jurgen ; Vitale, Antonio ; Emmi, Giacomo ; Vannozzi, Lorenzo ; Bacherini, Daniela ; Lopalco, Giuseppe ; Guerriero, Silvana ; Venerito, Vincenzo ; Orlando, Ida ; Franceschini, Rossella ; Fusco, Fiorella ; Frediani, Bruno ; Galeazzi, Mauro ; Iannone, Florenzo ; Tosi, Gian Marco ; Cantarini, Luca. / Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis. In: Ocular Immunology and Inflammation. 2017 ; pp. 1-6.
@article{5fc8f84f1d3c4815af152748587700bd,
title = "Ten-Year Retention Rate of Infliximab in Patients with Beh{\cc}et’s Disease-Related Uveitis",
abstract = "{\circledC} 2017, Taylor & Francis. All rights reserved. Purpose: To evaluate the 10-year drug retention rate of infliximab (IFX) in Beh{\cc}et’s disease (BD)-related uveitis, the effect of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on drug survival and differences according to the lines of biologic treatment. Methods: Cumulative survival rates were studied using the Kaplan-Meier plot, while the Log-rank (Mantel-Cox) test was used to compare survival curves. Results: Forty patients (70 eyes) were eligible for analysis. The drug retention rates at 12-, 24-, 60- and 120-month follow-up were 89.03{\%}, 86.16{\%}, 75.66{\%} and 47.11{\%} respectively. No differences were identified according to the use of concomitant DMARDs (p = 0.20), while a statistically significant difference was observed in relation to the different lines of IFX treatment (p = 0.014). Visual acuity improved from baseline to the last follow-up visit (p = 0.047) and a corticosteroid-sparing effect was observed (p  < 0.0001). Conclusions: IFX retention rate in BD-uveitis is excellent and is not affected by concomitant DMARDs.",
keywords = "Beh{\cc}et’s disease, drug retention rate, infliximab, treatment, uveitis",
author = "Claudia Fabiani and Jurgen Sota and Antonio Vitale and Giacomo Emmi and Lorenzo Vannozzi and Daniela Bacherini and Giuseppe Lopalco and Silvana Guerriero and Vincenzo Venerito and Ida Orlando and Rossella Franceschini and Fiorella Fusco and Bruno Frediani and Mauro Galeazzi and Florenzo Iannone and Tosi, {Gian Marco} and Luca Cantarini",
year = "2017",
month = "11",
day = "4",
doi = "10.1080/09273948.2017.1391297",
language = "English",
pages = "1--6",
journal = "Ocular Immunology and Inflammation",
issn = "0927-3948",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis

AU - Fabiani, Claudia

AU - Sota, Jurgen

AU - Vitale, Antonio

AU - Emmi, Giacomo

AU - Vannozzi, Lorenzo

AU - Bacherini, Daniela

AU - Lopalco, Giuseppe

AU - Guerriero, Silvana

AU - Venerito, Vincenzo

AU - Orlando, Ida

AU - Franceschini, Rossella

AU - Fusco, Fiorella

AU - Frediani, Bruno

AU - Galeazzi, Mauro

AU - Iannone, Florenzo

AU - Tosi, Gian Marco

AU - Cantarini, Luca

PY - 2017/11/4

Y1 - 2017/11/4

N2 - © 2017, Taylor & Francis. All rights reserved. Purpose: To evaluate the 10-year drug retention rate of infliximab (IFX) in Behçet’s disease (BD)-related uveitis, the effect of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on drug survival and differences according to the lines of biologic treatment. Methods: Cumulative survival rates were studied using the Kaplan-Meier plot, while the Log-rank (Mantel-Cox) test was used to compare survival curves. Results: Forty patients (70 eyes) were eligible for analysis. The drug retention rates at 12-, 24-, 60- and 120-month follow-up were 89.03%, 86.16%, 75.66% and 47.11% respectively. No differences were identified according to the use of concomitant DMARDs (p = 0.20), while a statistically significant difference was observed in relation to the different lines of IFX treatment (p = 0.014). Visual acuity improved from baseline to the last follow-up visit (p = 0.047) and a corticosteroid-sparing effect was observed (p  < 0.0001). Conclusions: IFX retention rate in BD-uveitis is excellent and is not affected by concomitant DMARDs.

AB - © 2017, Taylor & Francis. All rights reserved. Purpose: To evaluate the 10-year drug retention rate of infliximab (IFX) in Behçet’s disease (BD)-related uveitis, the effect of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on drug survival and differences according to the lines of biologic treatment. Methods: Cumulative survival rates were studied using the Kaplan-Meier plot, while the Log-rank (Mantel-Cox) test was used to compare survival curves. Results: Forty patients (70 eyes) were eligible for analysis. The drug retention rates at 12-, 24-, 60- and 120-month follow-up were 89.03%, 86.16%, 75.66% and 47.11% respectively. No differences were identified according to the use of concomitant DMARDs (p = 0.20), while a statistically significant difference was observed in relation to the different lines of IFX treatment (p = 0.014). Visual acuity improved from baseline to the last follow-up visit (p = 0.047) and a corticosteroid-sparing effect was observed (p  < 0.0001). Conclusions: IFX retention rate in BD-uveitis is excellent and is not affected by concomitant DMARDs.

KW - Behçet’s disease

KW - drug retention rate

KW - infliximab

KW - treatment

KW - uveitis

UR - http://www.scopus.com/inward/record.url?scp=85032795183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032795183&partnerID=8YFLogxK

U2 - 10.1080/09273948.2017.1391297

DO - 10.1080/09273948.2017.1391297

M3 - Article

AN - SCOPUS:85032795183

SP - 1

EP - 6

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

ER -